RE:HCG fires final bullet, RayJay plays catch-upThe $11 fall in RJ target is still several dollars higher than the current price. A decent return at current levels if she's right. And even after possible funding impacts which may or may not materialise, the stock still trades in the mid to upper single digits on a forward basis. I don't know about you, but unless the earnings decline is secular, it looks like a fairly deep value play.